Document:

<PAGE>
Note: Certain portions of this document have been marked "[C.I.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

                                                                   EXHIBIT 10(G)

                         2006 MICANOL LICENSE AGREEMENT

THIS AGREEMENT, made and entered into as of this 30 day of January 2006 by and
between Winston Laboratories, Inc., a Delaware Corporation located at 100
Fairway Drive, Suite 134, Vernon Hills, Illinois 60061 (hereafter referred to as
"Winston") and Sirius Laboratories, Inc., an Illinois corporation located at 100
Fairway Drive, Suite 130, Vernon Hills, Illinois 60061 (hereinafter referred to
as "Sirius") and:

                                WITNESSETH THAT:

     WHEREAS, Winston and Sirius entered into a License Agreement dated February
12, 2004 (the "2004 License Agreement"), which terminates automatically on
January 31, 2006, and Winston and Sirius mutually desire to enter into a new
Agreement herein.

     WHEREAS, Winston desires to grant and Sirius desires to obtain an exclusive
license to the Products referred to herein, and to all Proprietary Rights in the
Territory as hereinafter defined.

     NOW, THEREFORE, in consideration of the premises and mutual benefits to be
derived hereunder, Winston and Sirius agree that each intending to be legally
bound, hereby agree as follows:

                             ARTICLE 1 - DEFINITIONS

     For the purpose of this Agreement, the following terms shall be defined as
follows:

     1.1 "Affiliate(s)" shall mean an entity (i) which directly or indirectly
through one or more intermediaries controls, or is controlled by, or is under
common control with, Winston or Sirius respectively, (ii) which beneficially
owns or holds [c.i.] percent ([c.i.]%) or more of any

<PAGE>
class of the Voting Stock of Sirius or Winston, respectively, or (iii) [c.i.]
percent ([c.i.]%) or more of the Voting Stock (or in the case of a Person which
is not a corporation, [c.i.] percent ([c.i.]%) or more of the equity interest)
of which is beneficially owned or held by Sirius or Winston, respectively. The
term "control" means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of an entity,
whether through the ownership of Voting Stock, by contract or otherwise.

     1.2 "Confidential Information" shall mean any and all written information,
know-how and data, technical and/or non-technical, designated as confidential
and which relates to Products (or the manufacture or use thereof) or Proprietary
Rights.

     1.3 "Effective Date" shall be February 1, 2006.

     1.4 "Exclusive License" shall mean a license whereby Sirius's rights in the
Territory shall be sole and entire and shall operate to exclude all others
including Winston.

     1.5 "Improvements" shall mean all improvements, modifications, line
extensions, including a shampoo containing anthralin, or adaptations to any part
of the Products which have been formulated in a stable form and are intended to
enhance the performance of any of the Products or which might be of commercial
interest in the manufacture, supply or other dealings of or in the Products.

     1.6 "Minimum Royalty" shall have the definition set forth in paragraph 3.3.

     1.7 "Net Sales" shall mean the gross receipts from sales of Product to
third parties less deductions for (i) [c.i.] and any other [c.i.]; (ii) [c.i.];
and (iii) [c.i.] shall be [c.i.] from computation of Net Sales, but Net Sales
shall [c.i.].

     1.8 "Products" or "Product" shall mean all products and all Improvements of
such products containing anthralin, owned, controlled or licensed by Winston or
all Improvements of

December 28, 2005                                                   CONFIDENTIAL

                                  Page 2 of 16

<PAGE>

such Products by Sirius, either currently marketed or which could be marketed,
including the existing Psoriatec Product.

     1.9 "Proprietary Rights" shall mean any and all intellectual property
rights, including without limitation, patent rights and the Trademarks, in, to,
or covering the Products (including without limitation Improvements), and their
composition, their manufacture or their use in the Territory, including but not
be limited to inventions, ideas, know-how, technology and trade secrets.

     1.10 "Quarterly Period" shall mean each of the periods ending on the last
day of April, July, November and January during the term of this Agreement.

     1.11 "Royalty Year" shall mean the twelve-month period from February 1 to
January 31.

     1.12 "Territory" shall mean the United States of America and its
territories.

     1.13 "Trademarks" shall mean the trademarks, brief particulars of which are
set forth in Annexes I and II.

                       ARTICLE 2 - LICENSE; REPRESENTATION

     2.1 During the term of this Agreement, Winston hereby grants to Sirius and
its Affiliates an Exclusive License under the Proprietary Rights owned or
controlled by Winston in the Territory, to make, have made, use, market, sell
and distribute the Products. During the term of this Agreement, Sirius may not
grant sublicenses to the Products in the Territory without Winston's prior
written consent.

     2.2 Winston hereby represents and warrants to Sirius and its Affiliates
that it has not licensed, granted, sold, placed any lien upon or otherwise
transferred any rights to the Products or any Proprietary Rights which at any
time have been held by Winston, other than to Sirius

December 28, 2005                                                   CONFIDENTIAL

                                  Page 3 of 16

<PAGE>

under this or a previous agreement with Sirius.

                    ARTICLE 3 - ROYALTIES AND PURCHASE OPTION

     3.1 As to Products licensed to Sirius pursuant to Article 2, Sirius shall
pay Winston a royalty equal to 25% of Net Sales of Product sold by Sirius and
its affiliates in the Territory for the first $1,000,000 in yearly Net Sales and
15% on all Net Sales exceeding $1,000,000 each year for the entire term of this
Agreement, subject to the minimum royalty provisions contained in paragraph 3.2
below.

     3.2 In the event that earned royalties payable to Winston under Section 3.1
of this Agreement shall fail to amount to the Minimum Royalty, as defined below
in Section 3.3 of this Agreement, in any Royalty Year, Sirius [c.i.] and [c.i.];
provided however in the event any Product sold by Sirius hereunder in any
Royalty Year is subject to Competition from a newly introduced Generic Product,
then in the event the earned royalty does not meet the Minimum Royalty, [c.i.]
and [c.i.] with respect to such Royalty Year. "Competition" shall be deemed to
exist if [c.i.] after the [c.i.], the total unit sales of the Product by Sirius
[c.i.] compared to the [c.i.] sales of the Product. "Generic Product" shall mean
a [c.i.] anthralin cream product that [c.i.], or is represented to the trade
[c.i.], Product.

     3.3 The Minimum Royalty shall be three hundred thousand ($300,000) each
Royalty Year, payable [c.i.] as per Article 6.1 of this Agreement.

     3.4 Between from [c.i.] and until [c.i.] (so long as the Minimum Royalty
for 2006 exceeds [c.i.] of the Net Sales for the calendar year 2006), on the one
hand, and also from [c.i.] and until [c.i.], on the other hand, Sirius, [c.i.],
can purchase from Winston all rights to Products

December 28, 2005                                                   CONFIDENTIAL

                                  Page 4 of 16

<PAGE>
for a cash payment [c.i.] (a) [c.i.] or (b) [c.i.]. If Sirius does not [c.i.]
during either such time period specified above, Winston will then [c.i.]. Sirius
may [c.i.] by given written notice to Winston of such exercise within such time
periods together with remitting the applicable payment to Winston. Upon Sirius
making such payment to Winston, this Agreement shall terminate and (X) Sirius
shall be assigned by Winston and Sirius shall own all right, title and interest
in and to Product and the Proprietary Rights which had been licensed to Sirius
hereunder, and (Y) Sirius shall owe Winston no further amounts or royalties
regarding the Products whatsoever, and (Z) Winston agrees to execute such
documents, make such filings and take such other actions as are necessary or
useful to give full effect to all of the foregoing. If the later of the two
option dates described in this Article 3.4 has not been exercised by such time,
this Article 3.4 shall survive the expiration of this Agreement under Article
10.1 and continue pursuant to its terms. However, this Article 3.4 shall
terminate in its entirety in the event of a termination of this Agreement under
Article 10.2 occurring prior to the exercise of an option described in this
Article 3.4.

December 28, 2005                                                   CONFIDENTIAL

                                  Page 5 of 16

<PAGE>

                              ARTICLE 4 - PROMOTION

     4.1 During the term of this Agreement, Sirius agrees to [c.i.] to maintain
trade distribution of the Products.

                              ARTICLE 5 - INVENTORY

     5.1 Sirius shall be responsible for the production and manufacturing of all
Product inventory sold and distributed under the Agreement. Upon termination of
this Agreement Sirius shall [c.i.] and [c.i.] to Winston [c.i.]. Winston shall
not be [c.i.] any [c.i.] or [c.i.] with an expiration date that is within [c.i.]
of the [c.i.] of such inventory by Winston from Sirius.

                        ARTICLE 6 - PAYMENTS AND RECORDS

     6.1 On or before the last day of February, May, August and November of each
year during the term of this Agreement, Sirius shall provide Winston with a
complete written statement ("Report") showing the [c.i.]. Each Report shall
specify the [c.i.] and [c.i.], together with [c.i.] which shall have [c.i.]. The
[c.i.] sold shall be [c.i.] in (i) [c.i.], and (ii) [c.i.]. Sirius shall include
with this Report a [c.i.] to Winston [c.i.].

     In the event Sirius or its affiliates [c.i.] in accordance with this
Section 6.1, then Sirius shall [c.i.] at the rate of [c.i.] percentage points
over the [c.i.] from the date [c.i.] is due.

     6.2 During the term of this Agreement and for a period of [c.i.] years
after termination, Sirius shall keep true records and books of accounts of all
operations subject to this

December 28, 2005                                                   CONFIDENTIAL

                                  Page 6 of 16

<PAGE>

Agreement, including all data necessary for calculation of royalties payable to
Winston hereunder, and shall permit such records and books of account to be
examined, from time to time, during the regular business hours by a Certified
Public Accountant to such extent as may be reasonably necessary for Winston to
determine the accuracy of such calculation.

                       ARTICLE 7 - PATENTS AND TRADEMARKS

     7.1 It is agreed and understood that all of Winston's copyrights and
trademarks used in conjunction with Products including literature, trade dress
and labeling, is and shall remain the property of Winston.

     7.2 It is agreed that upon termination of this Agreement, Sirius shall
assign to Winston, [c.i.], all trademarks owned by Sirius solely relating to the
Products, including those listed in Annex II of this Agreement.

               ARTICLE 8 - GENERAL LIABILITY AND PRODUCT LIABILITY

     8.1 Sirius and its Affiliates shall indemnify, defend and hold Winston and
its Affiliates harmless against any and all [c.i.] including [c.i.], which
Winston or its Affiliates may hereinafter incur, suffer or be required to pay in
respect of any claims arising out of [c.i.] or [c.i.] under any [c.i.] or [c.i.]
following Sirius's completed purchase from Winston of the rights to the Products
and which results in [c.i.] of any person or animal caused or alleged to have
been caused by the use, sale, or manufacture of the Products by Sirius or its
Affiliates. This obligation shall survive expiry or any termination of this
Agreement.

     8.2 Sirius shall [c.i.] maintain with a reputable insurance company during
the life of this Agreement, and for the duration Sirius continues to market
Products following termination of this Agreement and for up to [c.i.],
appropriate product liability insurance covering the

December 28, 2005                                                   CONFIDENTIAL

                                  Page 7 of 16

<PAGE>
 warehousing, use, distribution, marketing, promotion and sale of the Products,
such insurance to provide cover to the extent required by local laws or
pharmaceutical industry practice, whichever is the higher, but in any case
[c.i.] dollars (US [c.i.]). Upon request of Winston, Sirius shall provide
Winston with a copy of the policy under which such insurance cover is provided
together with a copy of the most recent renewal receipt.

                      ARTICLE 9 - CONFIDENTIAL INFORMATION

     9.1 Winston and Sirius expressly acknowledge and agree that the
Confidential Information is highly valuable confidential and trade secret
information of each of the parties, and that the unauthorized disclosure by
Winston or Sirius of any part of the Confidential Information would cause
substantial and irreparable injury to the other party.

     9.2 Winston and Sirius shall both use their reasonable efforts and
diligence to safeguard the Confidential Information of the other party and to
protect it against disclosure, misuse, espionage, loss and/or theft. Neither
Winston nor Sirius shall disclose any of the Confidential Information of the
other party to any third party other than an Affiliate or marketing partner or a
prospective alternative supplier of the Products, except pursuant to
confidentiality agreements which impose no lesser obligations of confidentiality
than those set out in this Agreement. Neither Winston nor Sirius shall use any
of the Confidential Information of the other party except as permitted by this
Agreement. If either party is required by law or court order to disclose any
Confidential Information, it shall: (i) notify the other party in writing as
soon as possible, but in no event less than [c.i.] prior to any such disclosure,
if practicable; and (ii) use [c.i.] to preserve the confidentiality of such
Confidential Information consistent with applicable law and to limit any such
disclosure to the minimum disclosure necessary to comply

December 28, 2005                                                   CONFIDENTIAL

                                  Page 8 of 16

<PAGE>

with such law or court order. Notwithstanding anything to the contrary contained
herein, Winston or Sirius may, if necessary for purposes of filing for,
obtaining or maintaining regulatory approval of a Product or if otherwise
required by governmental authority, disclose Confidential Information to a
governmental authority for such purposes or if so required; provided, however,
that either party shall (i) notify the other party in writing no less than
[c.i.] prior to any such disclosure, if practicable, of the purpose for, and
Confidential Information to be included in, such disclosure; and (ii) take all
steps [c.i.] to limit any such disclosure as shall be reasonably necessary or
required and to request such governmental authority to maintain the
confidentiality of any information so disclosed.

     9.3 The obligations of this Article 9 do not apply to any information that:
(1) is or becomes publicly known or publicly disclosed or in the public domain
through no fault of the receiving party; (2) is already known to the receiving
party at the time of disclosure; (3) is independently developed by the receiving
party without the use of the information provided by the disclosing party; or
(4) is received by the receiving party from a third party under no obligation of
confidentiality to the disclosing party.

     9.4 Notwithstanding the foregoing confidentiality obligations, Sirius shall
not be deemed to have disclosed Confidential Information of Winston due to the
fact that such Confidential Information can be discerned from a Product, either
through reverse engineering or observation or due to the nature of the Product
itself.

     9.5 The obligations of this Article 9 shall survive any termination or
expiration of this Agreement and remain in full force and effect.

December 28, 2005                                                   CONFIDENTIAL

                                  Page 9 of 16

<PAGE>

                            ARTICLE 10 - TERMINATION

     10.1 Unless terminated earlier as provided in this Article 10 or under
Section 3.4, this Agreement shall expire on January 31, 2008, unless extended by
mutual written consent of both parties.

     10.2 Either party may terminate this Agreement upon the occurrence of any
of the following by giving the other party [c.i.] days' written notice:

          (i)  Upon or after bankruptcy, insolvency, or dissolution of the other
               party (except upon merger into a surviving corporation); or

          (ii) Upon or after the material breach of any provision of this
               Agreement by the other party if the breach is not cured within
               [c.i.] days after written notice thereof to the party in default.

     10.3 In the event of termination under Article 10.2: (a) all Confidential
Information supplied by either party to the other shall be returned forthwith to
the originating party; (b) the Proprietary Rights licensed to Sirius hereunder
shall forthwith rest with Winston; and (c) Winston agrees that it shall not use
the name or designation of Sirius or any of its Affiliates or, subject to
Section 7.2, any trademark owned or controlled by Sirius or any of its
Affiliates, in any marketing, promotional or sales activities relating to the
Products.

     10.4 Termination shall not extinguish any rights or obligations of the
parties which accrued prior to termination or either party's rights under
Section 3.4.

                      ARTICLE 11 - MISCELLANEOUS PROVISIONS

     11.1 Notice - Except as otherwise expressly provided herein, any notice,
consent or document required or permitted hereunder shall be given in writing
and it or any certificates or

December 28, 2005                                                   CONFIDENTIAL

                                 Page 10 of 16

<PAGE>

other documents delivered hereunder shall be deemed effectively given or
delivered (as the case may be) upon personal delivery (professional courier
permissible) or upon facsimile transmission (with receipt confirmed by
telephone), or on the third Business Day after being sent by United States
certified or registered mail (postage prepaid, return receipt requested) or the
seventh Business Day after being sent by international certified or registered
airmail (postage prepaid, return receipt requested). Such certificates,
documents or notice may be personally delivered to an authorized representative
of Sirius or Winston (as the case may be) at any address where such authorized
representative is present and otherwise shall be sent to the following address:

          If to Winston: Winston Laboratories, Inc.
                         100 Fairway Drive, Suite 134
                         Vernon Hills, Illinois 60061
                         Facsimile No.: (847) 362 8394
                         Attn: Joel E Bernstein, MD

          If to Sirius:  Sirius Laboratories, Inc.
                         100 Fairway Drive, Suite 130
                         Vernon Hills, Illinois 60061
                         Facsimile No.: (847) 968-2484
                         Attn: Frank Pollard

     11.2 Entire Agreement - This Agreement (including the schedules and
exhibits attached hereto) and the documents delivered pursuant hereto constitute
the entire agreement and understanding between the parties, and supersedes any
and all prior agreements and understandings relating to (a) the license,
purchase or sale of the Products or Proprietary Rights and (b) the subject
matter of this Agreement and the transactions contemplated thereby.

     11.3 Governing Law - This Agreement shall be interpreted, construed and
enforced in accordance with the laws of the [c.i.]. Jurisdiction for any legal
action brought under this Agreement will be in the [c.i.] and both parties agree
not to contest such jurisdiction.

     11.4 Force Majeure - The failure of either party to perform any term of
this Agreement when caused by or resulting from fire, floods, embargoes,
government regulations, wars, acts of

December 28, 2005                                                   CONFIDENTIAL

                                 Page 11 of 16

<PAGE>

war (whether war be declared or not), insurrections, riots, civil commotions,
strikes, lockouts, job actions, acts of God, or any other cause beyond the
control of such party, and which is a result thereof, shall not constitute a
default or breach under any term of this Agreement.

     11.5 Successors and Assigns - This Agreement shall be binding upon and
inure to the benefit of Winston and its successors and assigns and shall be
binding upon and inure to the benefit of Sirius and its successors and assigns;
provided, however, that neither party shall assign this Agreement or any of its
respective rights, duties or obligations hereunder without the prior written
consent of the other party, which consent shall not be unreasonably withheld;
provided that Sirius may assign this Agreement to its Affiliates. A merger or
acquisition involving Sirius or any of its Affiliates shall not be deemed to be
an assignment.

     11.6 Severability - Should any part of this Agreement for any reason be
declared invalid or unenforceable, such decision shall not affect the validity
or enforceability of any remaining portion, which remaining portion shall remain
in force and effect as if this Agreement had been executed with the invalid or
unenforceable portion thereof eliminated and it is hereby declared that the
intention of the parties hereto that they would have executed the remaining
portion of this Agreement without including therein any such part, parts, or
portion which may, for any reason, be hereafter declared invalid or
unenforceable. The parties shall endeavor to carry out the purpose of the
invalid or unenforceable portion to the extent permitted by law.

     11.7 Survival - Articles 7, 8 and 9 and any other provisions required to
interpret and enforce the parties' rights and obligations under this Agreement
shall survive the termination of this Agreement to the extent required for full
observation and performance of this Agreement by the parties in accordance with
its terms.

December 28, 2005                                                   CONFIDENTIAL

                                 Page 12 of 16

<PAGE>

     11.8 Arbitration. In the event of any dispute or difference arising out of
or relating to this Agreement, the parties hereto shall use their best endeavors
to settle such dispute or differences. To this effect they shall consult and
negotiate with each other, on good faith and understanding of their mutual
interests, to reach a just and equitable solution satisfactory to all parties.
If they do not reach such a solution within a period of [c.i.] days after notice
by one party to the other, then the disputes or differences shall be finally
settled by arbitration in accordance with Rules of [c.i.]. The arbitration shall
be conducted by [c.i.] selected and agreed by the parties hereto, or, in the
event that the parties are not able to agree on the selection of [c.i.] will
be appointed by the American Arbitration Association. The arbitration shall take
place in [c.i.]. The arbitration award [c.i.] on the parties, [c.i.] and shall
deal with the question of the costs of arbitration and all matters related
thereto. Judgement upon the award rendered may be entered in any court having
jurisdiction.

December 28, 2005                                                   CONFIDENTIAL

                                 Page 13 of 16

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in duplicate the day and year first above written.

WINSTON LABORATORIES, INC.              SIRIUS LABORATORIES, INC.

By: /s/ Joel E. Bernstein               By: /s/ Garry Barnes
    ---------------------------------       ------------------------------------
Title: CEO                              Title: President & CEO
Date: 1/30/06                           Date: 1/30/06

December 28, 2005                                                   CONFIDENTIAL

                                 Page 14 of 16

<PAGE>

                                     ANNEX I

                                 U.S. TRADEMARKS

<TABLE>
<CAPTION>
Trademark    Number   Class    Next renewal date
---------   -------   -----   ------------------
<S>         <C>       <C>     <C>
Micanol     2003319     5     September 24, 2006
</TABLE>

December 28, 2005                                                   CONFIDENTIAL

                                 Page 15 of 16

<PAGE>

                                    ANNEX II

                           TRADEMARKS OWNED BY SIRIUS

<TABLE>
<CAPTION>
Trademark    Number   Class   Next renewal date
---------    ------   -----   -----------------
<S>         <C>       <C>     <C>
Psoriatec   2780636    005     November 4, 2013
</TABLE>

December 28, 2005                                                   CONFIDENTIAL

                                 Page 16 of 16<PAGE>
Note: Certain portions of this document have been marked "[C.I.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

                                                                   EXHIBIT 10(H)

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
1.  DEFINITIONS..........................................................     1
2.  THE DEVELOPMENT AND COMMERCIALIZATION PROGRAMS.......................     5
    2.1   Overview of the Development Program............................     5
    2.2   Altana Responsibilities under the Development Program..........     5
    2.3   Company Responsibilities under the Development Program.........     6
    2.4   Overview of the Commercialization Program......................     6
    2.5   Company Responsibilities under the Commercialization Program...     6
    2.6   Altana Responsibilities under each Commercialization Program...     7
    2.7   Conduct of Development Program and Commercialization
          Activities.....................................................     7
    2.8   Manufacture and Supply of the Product..........................     7
    2.9   Non-Conforming Deliveries......................................     9
    2.10  Payment Responsibilities.......................................     9
3.  GOVERNANCE...........................................................     9
    3.1   General........................................................     9
    3.2   Certain Matters................................................     9
4.  ROYALTIES; MINIMUM ROYALTIES.........................................    10
    4.1   Royalties to Altana............................................    10
    4.2   Bartering Prohibited...........................................    10
    4.3   Minimum Royalties..............................................    10
5.  PAYMENTS AND REPORTS.................................................    10
    5.1   Payments.......................................................    10
    5.2   Royalty Payments...............................................    10
    5.3   Payment of Development Costs...................................    11
    5.4   Mode of Payment................................................    11
    5.5   Records Retention..............................................    11
    5.6   Audits.........................................................    11
    5.7   Taxes..........................................................    12
6.  INTELLECTUAL PROPERTY................................................    12
    6.1   License Grant to the Company...................................    12
    6.2   License Grant to Altana........................................    12
    6.3   Altana's Ownership.............................................    12
    6.4   Company's Ownership............................................    12
    6.5   Patent Prosecution and Maintenance of Inventions...............    12
    6.6   Patent and Trademark Enforcement...............................    13
    6.7   Infringement Actions by Third Parties..........................    13
7.  ADVERSE REACTION REPORTING...........................................    14
    7.1   Adverse Reaction Reporting.....................................    14
8.  REPRESENTATIONS AND WARRANTIES.......................................    14
    8.1   Representations and Warranties of Both Parties.................    14
    8.2   Warranties by Altana...........................................    15
    8.3   Warranties by the Company......................................    15
    8.4   Disclaimer.....................................................    15
9.  PRODUCT RECALLS......................................................    15
    9.1   ...............................................................    15
    9.2   ...............................................................    15
    9.3   ...............................................................    15
10. PUBLICATION; CONFIDENTIALITY.........................................    15
</TABLE>

                                       -i-

<PAGE>

<TABLE>
<S>                                                                         <C>
    10.1  Notification and Review with Respect to Altana and the
          Company........................................................    15
    10.2  Confidentiality: Exceptions....................................    16
    10.3  Exceptions to Obligation.......................................    16
    10.4  Remedies.......................................................    17
11. INDEMNIFICATION; INSURANCE...........................................    17
    11.1  By Altana......................................................    17
    11.2  By the Company.................................................    17
    11.3  Notice.........................................................    17
    11.4  Complete Indemnification.......................................    17
    11.5  Limitation on Liability........................................    17
    11.6  Insurance......................................................    18
12. TERM; TERMINATION....................................................    18
    12.1  Term...........................................................    18
    12.2  Termination for Cause..........................................    18
    12.3  Termination in Connection with Bankruptcy......................    18
    12.4  Effect of Expiration or Termination............................    18
    12.5  Accrued Rights: Surviving Obligations..........................    19
13. FORCE MAJEURE........................................................    19
14. MISCELLANEOUS........................................................    19
    14.1  Relationship of Parties........................................    19
    14.2  Assignment.....................................................    19
    14.3  Books and Records..............................................    19
    14.4  Further Actions................................................    19
    14.5  Notice.........................................................    20
    14.6  Use of Name....................................................    20
    14.7  Public Announcements...........................................    20
    14.8  Waiver.........................................................    21
    14.9  Compliance with Law............................................    21
    14.10 Severability...................................................    21
    14.11 Amendment......................................................    21
    14.12 Governing Law..................................................    21
    14.13 Arbitration....................................................    21
    14.14 Entire Agreement...............................................    22
    14.15 Parties in Interest............................................    22
    14.16 Descriptive Headings...........................................    22
    14.17 Counterparts...................................................    22
</TABLE>

                                      -ii-
<PAGE>

                                                                   EXHIBIT 10(H)

     THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this "Agreement"), dated
the _____ day of __________ 2005 (the "Effective Date"), is entered into by and
between Sirius Laboratories Inc., a corporation organized and existing under the
laws of the State of Illinois, having offices located at 100 Fairway Drive,
Suite 130, Vernon Hills, Illinois 60061, (the "Company" or "Sirius") and Altana
Inc., a corporation organized and existing under the laws of New York with
offices located at 60 Baylis Rd, Melville, New York 11747 ("Altana").

                             PRELIMINARY STATEMENTS

     A. Altana owns and has all right, title and interest in, or has acquired
the exclusive rights to the Altana Product IP (as defined below).

     B. The Company owns and has all right, title and interest in, or has
acquired the exclusive rights to the Company Technology IP (as defined below).

     C. Altana and the Company collectively possess specialized skills,
knowledge, and expertise in the development, marketing and sale of products used
in the treatment of diseases of the human skin, including without limitation,
[c.i.] and desire to enter into a development and license agreement regarding
the further development and the marketing of certain such products, the initial
development of which has been undertaken by Altana.

     D. In return for certain rights in the Product (as defined below), the
Company will, subject to the terms and conditions of this Agreement, (1) support
the Development Program (as defined below) financially as well as by providing a
license under the Company Technology IP (as defined below), and (2) pay Altana
certain royalties as provided for herein.

     E. Altana desires to continue its development of the Product and to apply
its skills, knowledge, and expertise in assisting the Company in obtaining the
regulatory approval of the Product under the terms and conditions set forth in
this Agreement.

     F. The Company desires to obtain an exclusive license to sell, offer to
sell and distribute the Product in the Territory (as defined below), and Altana
desires to grant such license to the Company and supply the Company with its
requirements of the Product, pursuant to the terms and conditions of this
Agreement.

     NOW, THEREFORE, in consideration of the foregoing Preliminary Statements
and the mutual agreements and covenants set forth herein, the Parties hereby
agree as follows:

1.   DEFINITIONS.

     As used in this Agreement and unless otherwise defined herein, the
following terms shall have the meanings set forth in this Section 1:

     "Agreement" shall have the meaning assigned to such term in the
introductory paragraph of this Agreement.

     "Affiliate" with respect to any Party, shall mean any entity controlling,
controlled by, or under common control with, such Party, for only so long as
such control exists. For these purposes, "control" shall refer to: (i) the
possession, directly or indirectly, of the power to direct the management or
policies of an entity, whether through the ownership of voting securities, by
contract or otherwise, or (ii) the ownership, directly or indirectly, of more
than [c.i.] of the voting securities or other ownership interest of an entity.

                                       -1-

<PAGE>

     "Allocable Overhead" shall have the meaning assigned to such term in the
Financial Appendix.

     "Altana" shall have the meaning assigned to such term in the introductory
paragraph of this Agreement.

     "Altana Product IP" shall mean, with respect to the Product, all Know-how,
trademarks and Patents owned or licensed by Altana as of the Effective Date, to
the extent relating to such Product.

     "Audited Party" shall have the meaning assigned to such term in Section
5.6(a).

     "Auditing Party" shall have the meaning assigned to such term in Section
5.6(a).

     "Breaching Party" shall have the meaning assigned to such term in Section
11.2.

     "cGMP" shall mean current good manufacturing practices, as established by
the FDA and all other applicable laws and regulations that apply and are in
effect at the time and place of manufacture, including without limitation, Good
Manufacturing Practice as defined in Parts 210 and 211 of Title 21 of the Code
of Federal Regulations, as may be amended from time to time, or any successor
thereto.

     [c.i.]

     "[c.i.] Invention" shall mean any new or useful process, compound,
composition of matter, method of use or Know-how, whether or not patentable,
related to the Product, and any improvement, enhancement, modification or
derivative work to any Company Technology Product IP; in each case, (a) which is
not a Product Invention, and (b) which is conceived or first reduced to practice
or first demonstrated to have utility during the term of this Agreement by
either Party in connection with the development or commercialization activities
contemplated in this Agreement.

     "Combination Sales" mean sales of a Product which are sold bundled in a
transaction with any other products or any service by the Company or its
Affiliates.

     "Commercialization Plan" shall have the meaning assigned to such term in
Section 2.4(a).

     "Company" shall have the meaning assigned to such term in the introductory
paragraph of this Agreement.

     "Company Technology IP" shall mean, the Company's intellectual property
with respect to [c.i.], all Know-how, trademarks and Patents owned or licensed
by the Company as of the Effective Date, to the extent relating to [c.i.] and
its use with the Altana Product IP.

     "Cost Estimate" shall mean the estimated costs of undertaking the
Development Plan as set forth in Section 2.1(b) and approved by the Parties from
time to time.

     "Confidential Information" shall have the meaning assigned to such term in
Section 9.2.

     "Development Costs" shall have the meaning assigned to such term in the
Financial Appendix.

     "Development Program" shall mean the Development Program defined in Section
2.1(a).

                                       -2-

<PAGE>

     "Development Plan" shall have the meaning assigned to such term in Section
2.1(b).

     "Effective Date" shall have the date first written above.

     "Expert" shall have the meaning set forth in Section 13.13(b)(i).

     "FDA" shall mean the United States Food and Drug Administration.

     "Field" shall mean the use of the Product(s) for the treatment of [c.i.].

     "Financial Appendix" shall mean Exhibit A hereto.

     "Firm Order" shall have the meaning set forth in Section 2.8(c).

     "First Commercial Sale" shall have the meaning assigned to such term in the
Financial Appendix.

     "Forecast" shall have the meaning set forth in Section 2.8(b).

     "Fully Absorbed Manufacturing Cost" shall have the meaning assigned to such
term in the Financial Appendix.

     "Fully Loaded Costs" shall have the meaning assigned to such term in the
Financial Appendix.

     "GAAP" shall mean generally accepted accounting principles in the United
States, consistently applied by the Parties.

     "Improvements" shall mean any and all new developments by the Company or
Altana relating to the Product(s) intended to enhance the performance and/or
improve the methods of manufacture and production techniques of the Product(s).
Improvements shall also include, without limitation, all developed or to be
developed formulations of the Product(s) under this Agreement pursuant to the
Development Plan.

     "IND" shall mean an effective Notice of a Claimed Investigational New Drug
Exemption as defined in Title 21 of the Code of Federal Regulations.

     "Indemnitee" shall have the meaning assigned to such term in Section 10.3.

     "Infringement" shall have the meaning assigned to such term in Section
6.5(c).

     "Know-how" shall mean any and all unpatented formulae, processes, trade
secrets, technologies and know-how, whether or not patentable, including,
without limitation, synthesis, preparation, recovery and purification processes
and techniques, control methods and assays, chemical data, toxicological and
pharmacological data and techniques, clinical data, medical uses, product forms
and product formulations and specifications.

     "Minimum Net Sales" shall have the meaning assigned to such term in Section
2.8.

     "Net Sales" shall have the meaning assigned to such term in the Financial
Appendix.

     "Non-breaching Party" shall have the meaning assigned to such term in
Section 11.2.

                                       -3-

<PAGE>

     "Party" shall mean, as applicable, Altana or Sirius and, when used in the
plural, shall mean Altana and the Company.

     "Patents" shall mean the patents and patent applications relating to
products in the Territory, together with any patents that may issue thereafter
in the Territory, including any and all extensions, renewals, continuations,
continuations-in-part, divisions, patents-of-additions, reissues; and a Patent
shall be any one of the foregoing.

     "Payment Period" shall have the meaning assigned to such term in Section
5.2(a).

     "Product(s)" shall mean Altana's pharmaceutical composition having [c.i.]
as its sole active pharmaceutical ingredient, [c.i.] by the Parties under this
Agreement pursuant to the Development Plan.

     "Product Invention" shall mean any new or useful process, compound,
composition of matter, method of use or Know-low, whether or not patentable,
related to the Product, and any Improvement, enhancement, modification or
derivative work to any Altana Product IP; in each case, conceived or first
reduced to practice or first demonstrated to have utility during the term of
this Agreement by either Party in connection with the development or
commercialization activities contemplated in this Agreement.

     "Registration" shall mean final approval of the Registration Application
for a Product in the Field which approval would allow the marketing and sale of
such Product in the Field in the Territory.

     "Registration Application" shall mean any filing(s) made with the FDA for
regulatory approval of the manufacture and sale of the Product in the Field in
the Territory.

     "Sales Costs" shall have the meaning assigned to such term in the Financial
Appendix.

     "Serious Adverse Drug Experience" shall have the meaning assigned to such
term in Section 7.1(b).

     "Special Arbitration Provisions" shall have the meaning assigned to such
term in Section 13.13(b).

     "Specifications" shall mean the approved specifications for raw materials
and manufacturing procedures of the Product as either specified by Altana from
time to time or as approved or required by FDA, as applicable and appropriate,
including, without limitation: (i) raw material specifications (including
approved suppliers, art proofs, chemical, micro, and packaging specifications);
(ii) sampling requirements (i.e., lab, chemical, and micro); (iii) compounding
module, including compounding process and major equipment; (iv) intermediate
specifications; (v) packaging module (including packaging procedures, torque and
fill weights); (vi) finished Product specifications release criteria including
Altana Acceptable Quality Limits ("AQL's"); (vii) stability specifications; and
(viii) test methods.

     "Steering Committee" shall have the meaning assigned to such term in
Section 3.1.

     "Territory" with respect to the Product shall mean [c.i.] including [c.i.].

     "Third Party" shall mean any person who or which is neither a Party nor an
Affiliate of a Party.

     "Term" shall have the meaning assigned to such term in Section 11.1.

                                       -4-

<PAGE>

     "Units" shall have the meaning assigned to such term in the Financial
Appendix.

2.   THE DEVELOPMENT AND COMMERCIALIZATION PROGRAMS.

     2.1 Overview of the Development Program.

          (a) The "Development Program" for the Product in the Territory shall
be comprised of all research, development, and regulatory activities related to
such Product in the Field and all filings, reports and related regulatory
interactions. Altana shall have responsibility for the execution of the
Development Program.

          (b) During the Term up to and including the Registration of the
Product, from time to time Altana shall, from time to time, prepare a proposed
Development Plan which shall be submitted to the Company for review and comment.
Such "Development Plan" shall mean the plan of research, development, and
regulatory activities to be undertaken as part of the Product's Development
Program as well as the estimated costs of undertaking such activities ("Cost
Estimate"). Altana shall take into good faith consideration the comments
received from the Company regarding any Development Plan. The Company's prior
approval of a Development Plan shall be required only to the extent a
Development Plan allocates responsibility to the Company for undertaking
activities as part of the Development Program. The initial Development Plan is
attached hereto as Exhibit B.

     2.2 Altana Responsibilities under the Development Program. As part of the
Development Program for the Product, in accordance with the Development Plan,
Altana shall:

          (a) use [c.i.] to conduct such research and development activities in
the Field [c.i.] to obtain Registration for the Product in the Territory,
including, (i) [c.i.]; (ii) [c.i.], including manufacture and supply of the
Product for use in the Development Program [c.i.]; (iii) [c.i.] outlined in the
Development Plan; and (iv) as specified in the Development Program, [c.i.].

          (b) conduct the Development Program in good scientific manner, and in
compliance in all material respects with all requirements of applicable laws,
rules and regulations, and all other requirements of any applicable cGMP, good
laboratory practice and current good clinical practice and to use [c.i.] to
achieve the objectives of the Development Program;

          (c) maintain records, in sufficient detail and in good scientific
manner, which shall be complete and accurate and shall fully and properly
reflect all work done and results achieved in connection with the Development
Program in the form required under all applicable laws and regulations. The
Company shall have the right, during normal business hours and upon reasonable
prior written notice, to inspect all such records at its own expense, so long as
doing so is not unreasonably disruptive. The Company shall maintain such records
and information contained therein in confidence in accordance with Section 9 and
shall not use such records or information except to the extent otherwise
permitted by this Agreement;

          (d) use [c.i.] to submit Registration Applications and obtain
Registrations for the Product in the Field in the Territory;

          (e) prepare and file response to inquiries of Regulatory Authorities
arising during review of the Product' dossier; and

          (f) use [c.i.] to perform such other responsibilities with respect to
the Development Program as may be mutually agreed upon by the Parties from time
to time.

                                       -5-

<PAGE>

     2.3 Company Responsibilities under the Development Program. As part of the
Development Program for the Product, in accordance with the Development Plan,
the Company shall:

          (a) use [c.i.] to assist Altana in conducting such research and
development activities in the Field necessary or desirable to obtain
Registration for the Product in the Territory and undertake [c.i.] relating to
the use [c.i.] in the Product;

          (b) assist and support Altana with respect to those regulatory filings
necessary to obtain Registration to manufacture, market and sell the Product in
the Field in the Territory; and

          (c) perform such responsibilities with respect to the Development
Program as may be mutually agreed upon by the Parties from time to time.

     2.4 Overview of the Commercialization Program.

          (a) The "Commercialization Program" for the Product shall be comprised
of (i) all marketing, advertising, promotional, launch (including pre-launch
marketing) sales activities and sales representative detailing plan for such
Product in the Field in the Territory including, without limitation, planned
budgets and expenditure; and (ii) all filings, reports and related regulatory
interactions and Phase IV studies, if any, required by the FDA to maintain
Registration in the Territory after the Registration of such Product in the
Field in the Territory. The Commercialization Program shall be undertaken in
accordance with a commercialization plan which, from time to time, shall be
proposed by the Company and submitted to Altana for review and comment (the
"Commercialization Plan"). The Company shall take into good faith consideration
the comments received from Altana regarding any Commercialization Plan. Altana's
prior approval of a Commercialization Plan shall be required only to the extent
a Commercialization Plan allocates responsibility to Altana for undertaking
activities as part of the Commercialization Program.

          (b) The Company, either itself and/or by and through its Affiliates,
shall be responsible for all activities comprising the Commercialization Program
for the Product.

     2.5 Company Responsibilities under the Commercialization Program. As part
of the Commercialization Program for a Product, in accordance with the
Commercialization Plan, the Company shall:

          (a) perform pre-commercialization analysis, planning, market
preparation and related marketing activities in the Territory;

          (b) carry out the distribution, marketing and sales of the Product in
the Territory using a level of diligence and resources substantially similar to
those that the Company applies to comparable products of the Company in the
Territory;

          (c) conduct [c.i.] and marketing [c.i.] for the Product in the
Territory;

          (d) conduct the Commercialization Program in compliance in all
material respects with applicable laws, rules and regulations;

          (e) maintain records, which shall be complete and accurate in all
material respects and shall fully and properly reflect all revenues in
connection with the Commercialization Program. Altana shall have the right,
[c.i.] and [c.i.], to inspect all such records, so long as doing so [c.i.].
[c.i.] shall bear any [c.i.] incurred by it in connection with any

                                       -6-

<PAGE>

such inspection. Altana shall maintain such records and information contained
therein in confidence in accordance with Section 9 and shall not use such
records or information except to the extent otherwise permitted by this
Agreement; and

          (f) undertake, and have primary responsibility for all communication
with the FDA, if required by FDA, in connection with the Company's marketing and
sales activities in the Territory, including the submission to the FDA for
approval all marketing materials used in the Territory.

     2.6 Altana Responsibilities under each Commercialization Program. As part
of the Commercialization Program for a Product Altana shall, in accordance with
the Commercialization Plan, [c.i.] to:

          (a) support the Company in the Company's efforts in maintaining
Registration for the Product in the Field in the Territory;

          (b) manufacture or have manufactured by Third Party the Product for
commercial sale in the Territory in accordance with such Product's
specifications set forth in the applicable Registration and cGMP in such
quantities as the Company shall notify Altana as necessary and appropriate to
meet market demand in the Territory; and

          (c) perform such other activities with respect to the
Commercialization Program as the Parties mutually agree in writing are necessary
or useful from time to time; provided, that, any such activities undertaken by
Altana with respect to the Commercialization Program shall (unless otherwise
agreed by the Parties) [c.i.] the Company at $[c.i.] per [c.i.], other than
[c.i.] which shall be invoiced and paid in accordance with Section 2.8(i). The
Company shall pay such invoices within [c.i.] days after receipt of same.

     2.7 Conduct of Development Program and Commercialization Activities. Each
Party, acting in accordance with this Section 2 when applicable, the Development
Plan and Commercialization Plan, when applicable, shall:

          (a) reasonably cooperate with the other Party, as requested by the
other Party with primary responsibility over the applicable development or
commercialization activities, as the case may be, to implement all such
activities and such other activities that, from time to time, the Parties agree
are necessary or useful for the commercial success of the Development Program
and the Commercialization Program; and

          (b) allow representatives of the other Party, upon [c.i.] notice and
[c.i.], to visit such Party's facilities where any Development Program or
Commercialization Program is being conducted, and consult, during such visits
and by telephone, with such Party's personnel performing work on any Development
Program or Commercialization Program, so long as such visits and consultations
[c.i.]. The other Party shall maintain any information received (whether by
observation or otherwise) during such visit in confidence in accordance with
Section 9 and shall not use such information except to the extent otherwise
permitted by this Agreement.

     2.8 Manufacture and Supply of the Product.

          (a) Altana shall manufacture the Product to cGMP standards in
accordance with the applicable specifications and in accordance with applicable
laws and regulations; provided however in the event of any future changes in
cGMP standards, applicable specifications, and/or applicable laws and
regulations, any of which individually, or which cumulatively, have a material
adverse effect on the Fully Absorbed Manufacturing Cost for the

                                       -7-

<PAGE>

Product, the Parties shall [c.i.]. Altana shall provide the Company with a
certificate of analysis and/or certificate of conformance for each batch of the
Product delivered to the Company.

          (b) Company shall submit to Altana, at least [c.i.] prior to the
[c.i.] during the Term, [c.i.] rolling forecast ("Forecast") of the quantity of
the Product the Company expects to order for manufacture during such period. The
Company shall make all Forecasts in good faith given market conditions and other
information available to the Company. Each Forecast shall [c.i.], with [c.i.]
reflected therein, which [c.i.], and Company shall place firm orders [c.i.] with
[c.i.] of each Forecast.

          (c) Altana shall use [c.i.] to manufacture and deliver to the Company
the Product that Company has ordered pursuant to a firm order by the requested
delivery date, provided that, the firm order was given at least [c.i.] prior to
the desired delivery date (each such order, a "Firm Order"). In any event, the
Company shall be required to place Firm Orders [c.i.]: (i) at least [c.i.]
pieces of the [c.i.] of the Product; and (ii) at least [c.i.] pieces of the
[c.i.] of the Product or multiples thereof. A Firm Order may not be cancelled,
and Company shall be obligated to pay the Purchase Price for said order.

          (d) Each Firm Order shall specify the Product, the quantity of the
Product ordered, the destination to which the Product is to be delivered and the
time and manner of delivery (including the carrier to be used) in accordance
with Section 2.8(h).

          (e) In the event that the quantity of the Product ordered by Company
pursuant to Section 2.8(c) for delivery in any month is more than the quantity
of the Product reflected in the most recent Forecast for such month, Altana
shall use [c.i.], but [c.i.]

          (f) Altana may reject any order upon the grounds that such order sets
forth a manufacture and delivery schedule that is inconsistent with this Section
2.8.

          (g) The Product shall be packaged and labeled in accordance with FDA
approved labeling as instructed by the Company, and shall be accompanied by
appropriate certificates of analysis. Product shall be appropriately labeled
with a traceable batch number and date of manufacture. Altana shall ship each
shipment, [c.i.], to the Company, or the Company's designee, at the location
specified in the applicable Firm Order, as instructed by the Company. All
[c.i.], as well as any special packing expenses, shall be borne by [c.i.]. The
risk of loss, delay or damage in transit shall be with [c.i.] from and after
[c.i.].

          (h) Subject to Section 2.8(g), Altana shall invoice Company at the
time of shipment for the applicable Purchase Price for the Product then shipped.
Each such invoice shall state the quantity of the Product contained in the
shipment in question. The Purchase Price for the Product until [c.i.] shall be
as follows: $[c.i.] per [c.i.] of the Product and [c.i.] per [c.i.] of the
Product. After [c.i.], the Purchase Price for the Product shall [c.i.] but by no
more than [c.i.] and with the result price being no more than [c.i.] Altana's
Fully Absorbed Manufacturing Cost for the Product. Altana shall give the Company
notice of each such price increase within [c.i.] following each [c.i.] and
[c.i.] shall be [c.i.].

          (i) The Company or its designee shall confirm the quantity of the
Product contained in any shipment. In the event the quantity of the Product
shipped is greater or less than the quantity reflected in Altana' invoice for
such shipment, then within [c.i.] after Company's or its designee's receipt of
such shipment, the Company shall notify Altana concerning such overage or
shortage. Unless Altana disputes such notice, the amount of such invoice
automatically shall be increased or reduced, as the case may be, to reflect the
actual quantity of the Product contained in such shipment.

                                       -8-

<PAGE>

     2.9 Non-Conforming Deliveries.

          (a) Product delivered by a Party to the other Party pursuant to
Sections 2.8 or 2.9 that does not conform with the applicable manufacturing
standards (as may be in effect from time to time) for any reason shall be deemed
to be non-conforming. It is the responsibility of the receiving Party to test or
cause to be tested all Product, as the case may be, upon receipt and to notify
the other Party of any alleged non-conformity within [c.i.] after receipt of the
shipment. A shipment will be considered accepted by the receiving Party unless
it gives such notice within such [c.i.] time period.

          (b) The delivering Party shall have the right to examine and test any
batch of the Product, as the case may be, that the receiving Party claims is
non-conforming and shall notify the receiving Party in writing of its findings.
In the event the Parties cannot agree as to whether any such batch is
non-conforming, the Parties shall designate an independent testing laboratory to
determine same, the findings of which shall be binding on the Parties, absent
manifest error. Expenses of such laboratory testing shall be borne by [c.i.].

          (c) In the event that any such batch is ultimately agreed or found to
be non-conforming, the delivering Party shall [c.i.] such shipment at its
expense.

     2.10 Payment Responsibilities.

          (a) The Company shall pay for all Development Costs incurred by the
Parties under the Development Program from the Effective Date and the costs and
expenses for each Commercialization Program. All Development Costs shall be
reported and paid pursuant to Section 5.3 and the Financial Appendix attached
hereto. If in any contract year the total Development Costs reported by Altana
to the Company exceed the Cost Estimates set forth in the Development Plan, then
Altana will review and report to the Company the reasons for the increased
expenditure and the Parties will consider revising such Cost Estimate upwards
and approving the increased expenditure.

          (b) Altana will undertake development work at a charge-out rate of
U.S. [c.i.] [c.i.] plus [c.i.].

3.   GOVERNANCE.

     3.1 General. The Parties shall in good faith consult and communicate with
one another as reasonably necessary and appropriate in undertaking the
activities contemplated by the Development Program and the Commercialization
Program so as to efficiently and expeditiously achieve the goals of the
Development Program and the Commercialization Program.

     3.2 Certain Matters. Without limiting the generality of Section 3.1, upon
the request of a Party, the Parties shall:

          (a) undertake a formal review and comparison of the status of the
Product's Development Program to the current Development Plan, including,
without limitation the applicable timelines (such formal review to be conducted,
if at all, no more frequently than [c.i.]);

          (b) undertake a formal review and comparison of the status of the
Product's Commercialization Program to the current Commercialization Plan,
including, without limitation the applicable timelines (such formal review to be
conducted, if at all, no more frequently than [c.i.]);

                                       -9-

<PAGE>

          (c) discuss or meet in an attempt to reasonably resolve disputes or
disagreements between the Parties relating to any aspect of the Development
Program or the Commercialization Program;

          (d) discuss or meet to decide whether and how to institute patent and
trademark Infringement actions against Third Parties in connection with the
Product; or

          (e) discuss or meet to determine a course of action in the event of
threatened or actual litigation in connection with Third Party Infringement
claims.

4.   ROYALTIES; MINIMUM ROYALTIES.

     4.1 Royalties to Altana. As consideration to Altana for the license and
other rights granted to the Company under this Agreement, in addition to the
Purchase Price for Product, the Company agrees to pay Altana royalties on Net
Sales of the Product as follows:

          (a) [c.i.] of all Net Sales of the Product in respect of such Net
Sales in each marketing year that are less than or equal to [C.I.]; and

          (b) [c.i.] of all Net Sales of the Product in respect of such Net
Sales in each calendar year that are greater than [C.I.].

     4.2 Bartering Prohibited. The Company and its Affiliates shall not accept
or solicit any bartered goods or services for the sale of the Product.

     4.3 Minimum Royalties. In the event royalty payments made under Section 4.1
for (a) the marketing year during the First Commercial Sale of the Product and
for the remainder of that marketing year, or (b) the first subsequent marketing
year do not equal or exceed $[c.i.] in royalty payments for such marketing year,
then the Company shall make an additional payment to Altana within [c.i.] of the
end of such marketing year such that a total of $[c.i.] in such royalty payments
shall have been made to Altana by the Company.

5.   PAYMENTS AND REPORTS.

     5.1 Payments. Payments to be made in connection with royalties payable on
Net Sales of the Product shall be made in accordance with Section 5.2. Payments
to be made in connection with Development Costs shall be made in accordance with
Section 5.3. All other payments to be made under this Agreement shall be made in
accordance with Section 5.4. The Parties shall also follow the periodic
reporting requirements set forth in the Financial Appendix.

     5.2 Royalty Payments. All royalty payments due by the Company under this
Agreement shall be paid to Altana [c.i.] within [c.i.] calendar days following
the end of [c.i.] ([c.i.] being a period of [c.i.].

          (a) (each such time period constituting a "Payment Period").

          (b) Each such royalty payment shall be accompanied by a statement
showing the amounts of Gross Sales, Net Sales, the components of each Net Sales
amount, the number of Units of the Product sold by Company and, if applicable,
by its Affiliates during such Payment Period (on a product-by-product basis),
and the amount of the royalty due on such Net Sales and the aggregate Net Sales
applicable to each such Product in the current marketing year-to-date.

                                      -10-
<PAGE>

          (c) Royalty payments for the Product shall commence as of the First
Commercial Sale of such Product in the Territory and shall terminate upon the
termination of this Agreement with respect of such Product(s).

     5.3 Payment of Development Costs. All Development Costs incurred by Altana
in accordance with a Development Program shall be reported to the Company by
Altana in the format shown on the Financial Appendix within [c.i.] days of the
end of each calendar month in accordance with the Financial Appendix and will be
reimbursed by the Company to Altana within [c.i.] calendar days of submission of
such report to Company showing such Development Costs.

     5.4 Mode of Payment. Each Party shall make all payments required under this
Agreement in [c.i.], via wire transfer of immediately available funds as
directed by the other Party from time to time, [c.i.]. Accounting for Net Sales
and royalties due under this Agreement shall be in [c.i.].

     5.5 Records Retention. The Parties shall keep complete and accurate records
pertaining to the milestones and sales achieved for the Product for a period of
[c.i.] after the year in which such activities occurred or sales were made, and
in sufficient detail to permit the other Party to confirm the accuracy of the
milestone and royalty payments made hereunder.

     5.6 Audits.

          (a) Either Party (herein, the "Auditing Party") may demand, no more
than [c.i.] for any marketing year in the term of this Agreement and only within
[c.i.] following the end of such marketing year, an audit of the relevant books
and records of the other Party (herein, the "Audited Party") in order to verify
the Audited Party's reports on the matters addressed in this Agreement. Upon no
less than [c.i.] days' prior written notice to the Audited Party, the Audited
Party shall grant reasonable access to members of a nationally recognized
independent public accounting firm selected by the Auditing Party to the
relevant books and records of the Audited Party in order to conduct a review or
audit thereof. Such access shall be permitted during normal business hours. The
Audited Party shall cooperate with such accounting firm and provide it access to
all records required in connection with such audit. The audit shall be complete
only when such accounting firm reasonably confirms that the audit is complete.
The accounting firm shall report its final conclusions and calculations to the
Auditing Party. In no event shall the accounting firm disclose any information
of the Audited Party to the Auditing Party except to the extent necessary to
verify the Audited Party's reporting and other compliance with the terms of this
Agreement and, at the request of the Audited Party, such accounting firm will
execute appropriate non-disclosure agreements. Except as otherwise provided in
Section 5.6(b), the Auditing Party shall bear the full cost of the performance
of any such audit.

          (b) If as a result of any audit of the books and records of the
Audited Party it is shown that a Party's payments to the other Party under this
Agreement with respect to the period of time audited were less or more than the
amount that should have been paid to the other Party pursuant to this Agreement,
then the Party that has been underpaid or the Party that has overpaid shall,
[c.i.] after submission of the final audit report to the Audited Party the other
Party's demand therefore, pay to the other Party the amount of such shortfall or
overpayment [c.i.] thereon. Such [c.i.] be calculated from the date such amount
was due until the date such amount is actually paid, at the rate of [c.i.] of
[c.i.] reported [c.i.] for the date such amount was due. In addition, if any
amount of underpayment by an Audited Party is more than [c.i.] of the amount
which should have been paid to the Auditing Party pursuant to this Agreement
with respect to the period in question as a result of incorrect reporting or
calculation by the Audited Party, then the Audited Party shall also reimburse
the Auditing Party for its documented

                                      -11-

<PAGE>

reasonable out-of-pocket costs and expenses incurred in connection with the
audit (including, without limitation, fees of attorneys, accountants and other
professionals).

     5.7 Taxes. In the event that a Party is mandated under the laws of a
country or other political subdivision of competent jurisdiction to withhold any
tax to the tax or revenue authorities in such jurisdiction in connection with
any payment to the other Party, such amount shall be deducted from the payment
to be made by such withholding Party; provided that the withholding Party shall
take reasonable and lawful actions to avoid and minimize such withholding and
promptly notify the other Party so that the other Party may take lawful actions
to avoid and minimize such withholding. The withholding Party shall promptly
furnish the other Party with copies of any tax certificate or other
documentation evidencing such withholding as necessary to satisfy the
requirements of the United States Internal Revenue Service related to any
application by such other Party for foreign tax credit for such payment. Each
Party agrees to reasonably cooperate with the other Party in claiming exemptions
from such deductions or withholdings under any agreement or treaty from time to
time in effect.

6.   INTELLECTUAL PROPERTY.

     6.1 License Grant to the Company. Subject to the terms and conditions of
this Agreement:

          (a) Altana hereby grants to the Company with respect to the Product an
exclusive license under the Altana Product IP and Product Inventions; in each
case, solely for the purpose of enabling the Company to use, market, sell, offer
for sale, import and distribute such Product in the Field in the Territory; and

          (b) Altana hereby grants to the Company with respect to the Product a
non-exclusive license under the Altana Product IP and Product Inventions; in
each case, solely for the purpose of enabling the Company to perform its
obligations under the Development Program for the Product.

          (c) The Company may [c.i.] under the license granted to it under
Section 6.1(a) [c.i.], which [c.i.].

     6.2 License Grant to Altana. Subject to the terms and conditions of this
Agreement, the Company hereby grants to Altana, with respect to the Product a
non-exclusive license under the Company Technology IP and [c.i.] Inventions; in
each case, solely for the purposes of enabling Altana to perform its obligations
under the Development Program for the Product, to manufacture and supply the
Product, and to exercise its rights to the Product in accordance with this
Agreement.

     6.3 Altana's Ownership. Altana shall solely own:

          (a) All [c.i.] and [c.i.] shall be the sole and exclusive property of
Altana; and

          (b) All [c.i.] shall be the sole and exclusive property of Altana.

     6.4 Company's Ownership. The Company shall solely own all [c.i.] including
all [c.i.] shall be the sole and exclusive property of Company.

     6.5 Patent Prosecution and Maintenance of Inventions.

          (a) [c.i.] shall have full responsibility for, and shall control the
preparation and prosecution of, all patent applications and the maintenance of
all patents relating to [c.i.].

                                      -12-

<PAGE>

[c.i.] shall pay all costs of filing, prosecuting and maintaining such patent
applications and patents relating to [c.i.]. [c.i.] shall have full
responsibility for, and shall control the preparation and prosecution of, all
patent applications and the maintenance of all patents relating to [c.i.].
[c.i.] shall pay all costs of filing, prosecuting and maintaining such patent
applications and patents relating to [c.i.].

          (b) [c.i.] shall determine whether any [c.i.] is patentable, and if
so, shall proceed with the preparation and prosecution of a patent application
covering any such [c.i.]. [c.i.] shall determine whether any [c.i.] is
patentable, and if so, shall proceed with the preparation and prosecution of a
patent application covering any such [c.i.].

          (c) Each Party agrees to cooperate with the other Party to execute all
lawful papers and instruments, to make all rightful oaths and declarations, and
to provide consultation and assistance as may be necessary in the preparation,
prosecution, maintenance and enforcement of all such patents owned or controlled
by the other Party pursuant to Sections 6.3, 6.4 and 6.5.

     6.6 Patent and Trademark Enforcement.

          (a) If either Party learns of an infringement, unauthorized use,
misappropriation or ownership claim or threatened infringement or other such
claim (an "Infringement") by a Third Party with respect to the Product or
Product-related trademarks within the Territory, such Party shall promptly
notify the other party in writing and shall promptly provide such other Party
with available evidence of such Infringement.

          (b) [c.i.] shall have the first right, but not the obligation, to
institute Product-related trademark Infringement actions against Third Parties
based on the Product-related trademark in the Territory as well as patent
Infringement actions against Third Parties based on the Product in the
Territory; provided that [c.i.] may not enter into any settlement, consent
judgment or other voluntary final disposition of such action which adversely
effects the Product or [c.i.] without the prior written consent of [c.i.], which
will not be unreasonably withheld. If [c.i.] does not effect a cessation of such
infringement or institute legal action for patent or trademark infringement one
or more infringing party or parties, [c.i.] shall have the right, but not the
obligation, to bring suit against said infringing party or parties at its own
expense. In the event of such a suit by [c.i.], [c.i.] will permit itself, at
[c.i.] to be joined as a party with [c.i.] in the suit if joinder is necessary
to confer upon [c.i.] the right to sue in the Territory. If either [c.i.] or
[c.i.] initiates a suit, the initiating Party shall be entitled to any monetary
recovery in such suit.

     6.7 Infringement Actions by Third Parties. In the event of the institution
or threatened institution of any suit by a Third Party against a Party for
patent or Product-related trademark infringement involving the manufacture, use,
distribution, sale or marketing of a Product in the Territory, such Party shall
promptly notify the other Party in writing of such suit. If the Third Party
action involves [c.i.] in the Territory, [c.i.] shall, [c.i.] defend both
Parties in such suit; provided that [c.i.], and provided further that [c.i.] may
not enter into any settlement, consent judgment or other voluntary final
disposition of such action which adversely effects the Product or [c.i.] without
the prior written consent of [c.i.], which will not be unreasonably withheld. If
the Third Party action involves the [c.i.] in the Territory, [c.i.] shall,
[c.i.], defend both Parties in such suit; provided that [c.i.], and provided
further that [c.i.] may not enter into any settlement, consent judgment or other
voluntary final disposition of such action which adversely effects the Product
or [c.i.] without the prior written consent of [c.i.], which will not be
unreasonably withheld. During the pendency of such action and thereafter, [c.i.]
shall [c.i.] under this Agreement. The proceeds of any such action received by
[c.i.] shall be retained by [c.i.], except that [c.i.] shall [c.i.], and [c.i.].
Either Party initiating such action shall keep the other Party reasonably
informed as to the status of such actions.

                                      -13-

<PAGE>

7.   ADVERSE REACTION REPORTING.

     7.1 Adverse Reaction Reporting. Altana shall record, evaluate, summarize
and review all adverse drug experiences associated with the Product, and report
all such information to the FDA in accordance with its regulatory requirements
as holder of the Product Registration. In addition, each Party shall:

          (a) [c.i.], provide to the other Party for initial and/or periodic
submission to the FDA significant information on the drug from preclinical
laboratory, animal toxicology and pharmacology studies, as well as adverse drug
experience reports from clinical trials and commercial experiences with each
Product;

          (b) in connection with investigational drugs, promptly report to the
other Party the receipt of a report of any unexpected serious adverse experience
with the drug, if required for either Party to comply with regulatory
requirements; and

          (c) in connection with marketed drugs, [c.i.] report to the other
Party any serious adverse drug experience promptly and in a time period which
will allow a Party to comply with its reporting obligations to the FDA.

          (d) Each Party shall promptly report to the other Party the
information set forth above affecting the Product in the Territory in accordance
with applicable law and the Pharmacovigilance Agreement referred to in Section
7.1(e). Each Party shall require that its Affiliates (i) adhere to all
requirements of applicable laws which relate to the reporting and investigation
of adverse drug experiences, and (ii) keep the Parties informed of such events
in accordance with the provision of this Section 7.

          (e) If a Party contracts with a Third Party for research to be
performed by such Third Party on the Product, that Party shall require such
Third Party to report to the contracting Party the information set forth above.

          (f) At least [c.i.] prior to the anticipated commercial launch of the
first Product, the Parties shall enter into a Pharmacovigilance Agreement, in
form and substance reasonably satisfactory to the Parties, which shall provide
the details of adverse reaction reporting requirements to the Parties during
Development Program(s) and thereafter that are not of the nature described
above.

8.   REPRESENTATIONS AND WARRANTIES.

     8.1 Representations and Warranties of Both Parties. Each Party represents
and warrants to the other Party, as of the Effective Date, that:

          (a) Such Party is duly organized and validly existing under the laws
of the jurisdiction of its incorporation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof;

          (b) Such Party has taken all corporate action necessary to authorize
the execution and delivery of this Agreement and the performance of its
obligations under this Agreement and has full power and authority to enter into
this Agreement and perform its obligations under this Agreement;

          (c) This Agreement has been duly executed by such Party and assuming
due authorization, execution and delivery by the other Party, constitutes a
valid and legally binding obligation of such Party, enforceable in accordance
with its terms, subject to and limited by: (i)

                                      -14-

<PAGE>

applicable bankruptcy, insolvency, reorganization, moratorium, and other laws
generally applicable to creditors' rights; and (ii) judicial discretion in the
availability of equitable relief;

          (d) Such Party has obtained, or is not required to obtain, the
consent, approval, order, or authorization of any Third Party, or has completed,
or is not required to complete any registration, qualification, designation,
declaration or filing with, the FDA, in connection with the execution and
delivery of this Agreement and the performance by such Party of its obligations
under this Agreement, including any grant of rights to the other Party pursuant
to this Agreement; and

          (e) The execution and delivery of this Agreement, and the performance
by such Party of its obligations under this Agreement, including the grant of
rights to the other Party pursuant to this Agreement, does not and will not: (i)
conflict with, nor result in any violation of or default under any instrument,
judgment, order, writ, decree, contract or provision to which such Party is
bound; (ii) give rise to any lien, charge or encumbrance upon any assets of such
Party or the suspension, revocation, impairment, forfeiture or non-renewal of
any material permit, license, authorization, or approval that applies to such
Party, its business or operations or any of its assets or properties, except any
or all of which could not reasonably be expected to have a material adverse
effect on its ability to perform its obligations under this Agreement or on the
rights of the other Party under this Agreement; or (iii) conflict with any
rights granted by such Party to any Third Party or breach any obligation that
such Party has to any Third Party.

     8.2 Warranties by Altana. Altana represents and warrants to the Company
that all Products manufactured and supplied under this Agreement shall [c.i.]
standards and [c.i.] when delivered [c.i.] in accordance with this Agreement.

     8.3 Warranties by the Company. The Company represents and warrants that the
sale of Products under and use of all labeling copy and artwork approved,
designated or supplied by the Company in connection with this Agreement shall be
[c.i.] and [c.i.] and [c.i.], to the [c.i.].

     8.4 Disclaimer. [C.I.].

9.   PRODUCT RECALLS

     In the event (i) any government authority issues a request, directive or
order that Product be recalled, or (ii) a court of competent jurisdiction orders
such a recall, or (iii) [c.i.] reasonably determines after consultation with
[c.i.] that the Product should be recalled because the Product does not conform
to Specifications at [c.i.], or (iv) [c.i.] reasonably determines that the
Product should be recalled for any reason, the Parties shall take all
appropriate corrective actions reasonably requested by the other Party hereto or
by any government agency.

     In the event that such recall results from [c.i.] under this Agreement,
[c.i.] shall be responsible for the [c.i.]. In the event the recall results from
[c.i.] under this Agreement, [c.i.] shall be responsible for the [c.i.]. In all
other events, [c.i.].

     For the purposes of this Agreement, the expenses of the recall shall be the
expenses of [c.i.].

10.  PUBLICATION; CONFIDENTIALITY.

     10.1 Notification and Review with Respect to Altana and the Company.

          (a) Both Parties recognize that each may wish to publish the results
of their work relating to the subject matter of this Agreement. However, both
Parties also recognize the

                                      -15-

<PAGE>

importance of acquiring patent protection and otherwise maintaining the
confidentiality of commercially sensitive information. Consequently, any
proposed publication, by either Party (including its Affiliates), that includes
information related to the Product or any Development Program, or which
otherwise includes proprietary information of the other Party or Confidential
Information, may not be made by either Party without the prior written consent
of the other Party, which shall not be unreasonably withheld or delayed.

          (b) Each Party agrees not to make any public announcement or
disclosure (including, without limitation, any press release, summary or Q&A) of
the terms of this Agreement or the documents ancillary thereto, or the identity
or potential applications of the Product, without first obtaining the prior
written approval of the other Party and agreement upon the nature and text of
such public announcement or disclosure. Notwithstanding the foregoing, on or
after the Effective Date, either Party may issue a press release, the content of
which will be agreed upon in advance by the Parties, with respect to the
execution of this Agreement. The Party desiring to make any such public
announcement shall provide the other Party with a copy of the proposed
announcement for review, comment and approval in reasonably sufficient time
prior to public release.

          (c) Each Party shall cooperate fully with the other with respect to
all disclosures regarding this Agreement required under applicable rules and
regulations promulgated by the United States Securities and Exchange Commission
and any other governmental or regulatory agency; provided, that, nothing herein
shall restrict a Party from making any disclosure that is required by law.

          (d) In addition, neither Party shall disclose, under any circumstances
except as set forth in this Section 9 or as otherwise required by law, the terms
of this Agreement or the identity or potential applications of the Product to
any Third Party other than to professional advisors and financing sources, and
in that case, only under confidentiality terms at least as stringent in material
respects as this Section 9.

     10.2 Confidentiality: Exceptions. Except to the extent expressly authorized
by this Agreement or otherwise agreed in writing, during the term of this
Agreement and [c.i.] following termination of this Agreement, the receiving
Party shall keep, and shall ensure that its Affiliates, employees, officers,
directors and agents keep, confidential and shall not publish or otherwise
disclose and shall not use for any purpose except to effectuate the purposes of
this Agreement (a) any information furnished to it by the other Party, or (b)
any information developed under or in connection with this Agreement by the
other Party; except to the extent that it can be established by the receiving
Party by competent proof that such information: (i) was already known to the
receiving Party, other than under an obligation of confidentiality, at the time
of disclosure by the other Party; (ii) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the
receiving Party; (iii) became generally available to the public or was otherwise
part of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; or (iv) was
disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party who was not known to the receiving Party to be
under an obligation to the disclosing Party not to disclose such information to
others (all such information to which none of the foregoing exceptions applies,
"Confidential Information").

     10.3 Exceptions to Obligation. The restrictions contained in Section 9.2
shall not apply to Confidential Information that (a) is submitted by the
receiving Party to Regulatory Authorities to facilitate the issuance of
Registrations for the Product, provided that reasonable measures are taken to
assure continued confidential treatment (to the extent permitted by the FDA) of
such information; (b) is provided by the receiving Party to Third Parties under
confidentiality agreements having provisions at least as stringent as those in
this Agreement in

                                      -16-

<PAGE>

connection with the receiving Party's responsibilities under the Development
Program and Commercialization Program; (c) is otherwise required to be disclosed
in compliance with applicable laws or regulations or order by a court or other
regulatory body having competent jurisdiction; provided that if a receiving
Party is required to make any such disclosure of the other Party's Confidential
Information, the receiving Party shall give reasonable advance written notice,
if practicable, to the other Party of such disclosure requirement and, except to
the extent inappropriate in the case of patent applications, will use its best
efforts to secure confidential treatment of such Confidential Information
required to be disclosed; or (d) was developed by the receiving Party
independent of any disclosure received under this Agreement. In addition, the
restrictions contained in Section 9.2 shall not apply to Altana to the extent
the Confidential Information relates to any application of Inventions (i)
outside the Territory, whether or not in the Field, or (ii) outside the Field,
whether or not in the Territory.

     10.4 Remedies. Each Party shall be entitled, in addition to any other right
or remedy it may have, at law or in equity, to apply for an injunction, without
the posting of any bond or other security, enjoining or restraining the other
Party from any violation or threatened violation of this Section 9.

11.  INDEMNIFICATION; INSURANCE.

     11.1 By Altana. Altana shall indemnify, defend and hold harmless the
Company and its Affiliates, and their respective directors, officers, employees
and agents, from and against any and all [c.i.] arising out of or resulting
from:

          (a) [c.i.] of Altana or its Affiliates, and their respective
directors, officers, employees and agents, in connection with the activities
contemplated under this Agreement or in the fulfillment of Altana's obligations
hereunder; or

          (b) any [c.i.] pursuant to Section [c.i.].

     11.2 By the Company. The Company shall indemnify, defend and hold harmless
Altana and its Affiliates, and their respective directors, officers, employees
and agents, from and against any and all [c.i.] arising out of or resulting
from:

          (a) [c.i.] of the Company or its Affiliates, and their respective
directors, officers, employees and agents, in connection with the activities
contemplated under this Agreement or in the fulfillment of Company's obligations
hereunder; or

          (b) any [c.i.] pursuant to Section [c.i.].

     11.3 Notice. In the event that any person (an "Indemnitee") entitled to
indemnification under Section 10.1 or 10.2 is seeking such indemnification, such
Indemnitee shall inform the indemnifying Party of the claim as soon as
reasonably practicable after such Indemnitee receives notice of such claim,
shall permit the indemnifying Party to assume direction and control of the
defense of the claim (including the sole right to settle it at the sole
discretion of the indemnifying Party, provided that such settlement does not
impose any obligation on the Indemnitee or the other Party or require any
admission of wrongdoing) and shall cooperate as requested (at the expense of the
indemnifying Party) in the defense of the claim.

     11.4 Complete Indemnification. As the Parties intend complete
indemnification, [c.i.] by an Indemnitee in connection with enforcement of this
Section 10 shall also be reimbursed by the indemnifying Party.

     11.5 Limitation on Liability. [C.I.].

                                      -17-

<PAGE>

     11.6 Insurance.

          (a) Each Party shall maintain, during the performance of this
Agreement, adequate insurance, with an insurance company reasonably acceptable
to the other Party, in amounts no less than that specified for each type:

               (i)  Product liability insurance with limits of not less than
                    [c.i.] and

               (ii) Excess insurance, in excess of all coverages set forth
                    above, with limits not less than [c.i.].

          (b) Each Party shall provide to the other at least [c.i.] prior
written notice of any cancellation or change in its foregoing insurance
coverage.

12.  TERM; TERMINATION.

     12.1 Term. This Agreement shall become effective as of the Effective Date
and, unless earlier terminated pursuant to the other provisions of this Section
11 or extended by written agreement of the Parties, shall expire [c.i.] from the
First Commercial Sale ("Term"). Upon consent of both Parties this Agreement may
be extended for an [c.i.] term.

     12.2 Termination for Cause. Either Party (the "Non-breaching Party") may,
without prejudice to any other remedies available to it at law or in equity,
terminate this Agreement in its entirety in the event the other Party (the
"Breaching Party") shall have materially breached or defaulted in the
performance of any of its material obligations hereunder; provided, that, such
breach or default shall have continued for [c.i.] after written notice thereof
was provided to the Breaching Party by the Non-breaching Party. Any such
termination shall become effective at the end of such [c.i.] period unless the
Breaching Party has cured any such breach or default prior to the expiration of
such [c.i.] period. The right of either Party to terminate this Agreement as
provided in this Section 11.2 shall not be affected in any way by its waiver or
failure to take action with respect to any previous default.

     12.3 Termination in Connection with Bankruptcy. Either Party may terminate
this Agreement, if, at any time, the other Party shall (i) file in any court or
agency pursuant to any statute or regulation of any state or country, a petition
in bankruptcy or insolvency or for its reorganization or for an arrangement or
for the appointment of a receiver or trustee of the Party or of substantially
all of its assets; or (ii) propose a written agreement of composition or
extension of substantially all of its debts; or (iii) be served with an
involuntary petition against it, filed in any insolvency proceeding, and such
petition shall not be dismissed within [c.i.] after the filing thereof; or (iv)
propose or be a party to any dissolution or liquidation; or (v) make an
assignment of substantially all of its assets for the benefit of creditors.

     12.4 Effect of Expiration or Termination. At the expiration or termination
of this Agreement for any reason, in addition to any other remedies available to
either Party at law or in equity: (i) [c.i.] each party shall promptly transfer
to the other party copies of all relevant data, reports, records and materials
in their possession or control that relate to the Product and return to the
other party all relevant records and materials in their possession or control
containing Confidential Information of the other party relating to the Product
(provided that the each party may keep one copy of such Confidential Information
of the other party for archival purposes only); (ii) the licenses granted to
each Party under Sections 6.1 and 6.2 shall terminate; and (iii) each Party
agrees that it shall not sell or otherwise commercialize the Product that is
developed by the Parties hereunder without first obtaining the written consent
of the other Party in addition to any other rights such Party may need to
undertake such activities.

                                      -18-

<PAGE>

     12.5 Accrued Rights: Surviving Obligations.

          (a) Termination, relinquishment or expiration of this Agreement for
any reason shall be without prejudice to any rights that shall have accrued to
the benefit of either Party prior to such termination, relinquishment or
expiration. Such termination, relinquishment or expiration shall not relieve
either Party from obligations that are expressly indicated to survive
termination or expiration of this Agreement.

          (b) All of the Parties' rights and obligations under Sections 5.5,
5.6, 6.3, 6.4, 6.5, 6.7, 8, 9, 10, 11, 12, 13 and 14 shall survive termination,
relinquishment or expiration of this Agreement.

13.  FORCE MAJEURE.

     Neither Party shall be held liable or responsible to the other Party nor be
deemed to be in default under, or in breach of any provision of, this Agreement
for failure or delay in fulfilling or performing any obligation of this
Agreement when such failure or delay is due to Force Majeure, and without the
fault or negligence of the Party so failing or delaying. For purposes of this
Agreement, Force Majeure is defined as causes beyond the control of the Party,
including, without limitation, acts of God; acts, regulations, or laws of any
government adopted after the date of this Agreement or subject to a new
interpretation after the date of this Agreement that render impossible or
illegal performance by a Party of its obligations under this Agreement; war;
civil commotion; destruction of production facilities or materials by fire,
flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure
of public utilities or common carriers. In such event Altana or the Company, as
the case may be, shall immediately notify the other Party, with written notice
to follow, of such inability and of the period for which such inability is
expected to continue. The Party giving such notice shall thereupon be excused
from such of its obligations under this Agreement as it is thereby disabled from
performing for so long as it is so disabled. Upon termination of a Force Majeure
event, the performance of any suspended obligation or duty shall promptly
recommence. To the extent possible, each Party shall use reasonable efforts to
minimize the duration of any Force Majeure.

14.  MISCELLANEOUS.

          14.1 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. No Party shall incur any debts or make
any commitments for the other, except to the extent, if at all, specifically
provided herein.

          14.2 Assignment. Neither Party shall be entitled to assign its rights
or delegate its obligations hereunder without the express written consent of the
other Party hereto, except that each Party may assign its rights and transfer
its duties hereunder to (i) an Affiliate or (ii) any assignee of all or
substantially all of its business or in the event of such Party's merger,
consolidation or involvement in a similar transaction. No assignment and
transfer shall be valid or effective unless done in accordance with this Section
13.2 and unless and until the assignee/transferee shall agree in writing to be
bound by the provisions of this Agreement.

          14.3 Books and Records. Any books and records to be maintained under
this Agreement shall be maintained in accordance with GAAP.

          14.4 Further Actions. Each Party shall execute, acknowledge and
deliver such further instruments, and do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

                                      -19-

<PAGE>

     14.5 Notice.

          (a) Except for notices given pursuant to Section 7.1, any notice or
request required or permitted to be given under or in connection with this
Agreement shall be deemed to have been sufficiently given if in writing and (i)
personally delivered; (ii) sent electronically or by facsimile transmission (in
each case with receipt verified) followed promptly by certified mail (return
receipt requested); or (iii) overnight express courier service (signature
required), prepaid, to the Party for which such notice is intended, at the
address set forth for such Party below:

               (i)  in the case of Altana, to:

                    Altana
                    Attention: Vice President of Business
                               Development & Procurement
                    P.O. Box 2006
                    60 Baylis Road
                    Melville, NY 11747
                    Phone: (631) 454-7677
                    Fax: (631) 420-1572

               (ii) in the case of the Company, to:

                    Sirius Laboratories, Inc.
                    100 Fairway Drive, Suite 130
                    Vernon Hills, IL 60061
                    Attention: Chief Executive Officer
                    Facsimile No.: 847-968-2484

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. With respect to notices given pursuant to
Section 7.1 or this Section 13.5, (i) if delivered personally or by facsimile
transmission, the date of delivery shall be deemed to be the date on which such
notice or request was given; (ii) if sent by overnight express courier service,
the date of delivery shall be deemed to be the next business day after such
notice or request was deposited with such service; and (iii) if sent by
certified mail, the date of delivery shall be deemed to be the third business
day after such notice or request was deposited with the postal service.

          (b) All correspondence, notices and other communications shall be
promptly provided to the other Party.

     14.6 Use of Name. Except as otherwise provided herein, neither Party shall
have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name, trademark or logo of the
other Party for any purpose in connection with the performance of this
Agreement.

     14.7 Public Announcements. Except as required by law (including, without
limitation, disclosure requirements of the U.S. Securities and Exchange
Commission, NASDAQ or any other stock exchange on which securities issued by a
Party or a Patty's Affiliates are traded) and as permitted by Section 9, neither
Party shall make any public announcement concerning this Agreement or the
subject matter hereof without the prior written consent of the other, which
shall not be unreasonably withheld, provided that it shall not be unreasonable
for a Party to withhold consent with respect to any public announcement
containing any financial terms or any of such

                                      -20-

<PAGE>

Party's Confidential Information. In the event of a required public
announcement, to the extent practicable under the circumstances, the Party
making such announcement shall provide the other Party with a copy of the
proposed text prior to such announcement and with financial terms sufficiently
in advance of the scheduled release of such announcement to afford such other
Party a reasonable opportunity to review and comment upon the proposed text.

     14.8 Waiver. A waiver by either Party of any of the terms and conditions of
this Agreement in any instance shall not be deemed or construed to be a waiver
of such term or condition for the future, or of any subsequent breach hereof.
All rights, remedies, undertakings, obligations and agreements contained in this
Agreement shall be cumulative and none of them shall be in limitation of any
other remedy, right, undertaking, obligation or agreement of either Party.

     14.9 Compliance with Law. Nothing in this Agreement shall be deemed to
permit a Party to export, re-export or otherwise transfer the Product sold under
this Agreement without compliance with applicable laws.

     14.10 Severability. When possible, each provision of this Agreement shall
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement.

     14.11 Amendment. No amendment, modification or supplement of any provisions
of this Agreement shall be valid or effective unless made in writing and signed
by a duly authorized officer of each Party.

     14.12 Governing Law. This Agreement shall be governed by and interpreted in
accordance with the laws of the [c.i.] without regard to conflict of law
principles. Each Party irrevocably consents and agrees that any legal action,
suit or proceeding with respect to any obligation, liability or other matter
under or arising out of or in connection with this Agreement, may be brought in
a federal or state court located in [c.i.], and each Party irrevocably accepts
and submits to the exclusive personal jurisdiction of such court with respect to
any such action, suit or proceeding. Each Party waives any objection which it
may now or hereafter have to the laying of venue of any such action, suit or
proceeding brought in any such court and hereby further waives its right to
assert and agrees not to plead or claim in any such court that any such action,
suit or proceeding brought therein has been brought in an inconvenient forum.

     14.13 Arbitration. Any dispute arising out of or relating to the
interpretation of any provisions of this Agreement or the failure of any Party
to perform or comply with any obligations or conditions applicable to such Party
pursuant to this Agreement shall be first attempted to be settled by referring
the dispute to the Chief Executive Officer of Altana, Inc. on behalf of Altana,
or such other person holding a similar position designated by Altana from time
to time, and the Chief Executive Officer of the Company, or such other person
holding a similar position designated by the Company from time to time. Failing
resolution by such executive officers of the Parties, either Party may elect at
any time thereafter to finally settle such dispute by arbitration under the then
current commercial arbitration rules of the American Arbitration Association in
accordance with the terms set forth in this Section 13.13:

          (a) The place of arbitration of any dispute shall be [c.i.]. Such
arbitration shall be conducted by three arbitrators, one appointed by each of
Altana and the Company and the third selected by the first two appointed
arbitrators. Each arbitrator shall be a person with relevant experience in the
pharmaceutical industry. Altana and the Company shall instruct such

                                      -21-

<PAGE>

arbitrators to render a determination of any such dispute within four months
after the appointment of the third arbitrator (or such other time as maybe
mutually agreed by the Parties).

          (b) Any award rendered by the arbitrators shall be final and binding
upon the Parties. Judgment upon any award rendered may be entered in any court
having jurisdiction, or application may be made to such court for a judicial
acceptance of the award and an order of enforcement, as the case may be. Each
Party shall pay its own expenses of arbitration, and the expenses of the
arbitrators shall be equally shared between the Parties unless the arbitrators
assess as part of their award all or any part of the arbitration expenses of a
Party or Parties (including reasonable attorneys' fees) against the other Party
or Parties, as the case may be.

          (c) This Section 13.13 shall not prohibit a Party from seeking
injunctive relief from a court of competent jurisdiction in the event of a
breach or prospective breach of this Agreement by any other Party which would
cause irreparable harm to the first Party.

     14.14 Entire Agreement. This Agreement, together with the Exhibits hereto
and the Development Plan, sets forth the entire agreement and understanding
between the Parties as to the subject matter hereof and merges all prior
discussions and negotiations between them, and neither of the Parties shall be
bound by any conditions, definitions, warranties, understandings or
representations with respect to such subject matter other than as expressly
provided herein or as duly set forth on or subsequent to the date hereof in
writing and signed by a proper and duly authorized officer or representative of
the Party to be bound thereby.

     14.15 Parties in Interest. All of the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable by
the Parties hereto and their respective successors and permitted assigns.

     14.16 Descriptive Headings. The descriptive headings of this Agreement are
for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement. References to Sections
herein shall refer to Sections of this Agreement unless otherwise specified.

     14.17 Counterparts. This Agreement may be executed simultaneously in any
number of identical counterparts, any one of which need not contain the
signature of more than one Party, but all such counterparts taken together shall
constitute one and the same agreement. Signatures provided by facsimile
transmission shall be deemed to be original signatures.

                                      * * *

                                      -22-

<PAGE>

     IN WITNESS WHEREOF, each of the Parties has caused this Development,
License and Supply Agreement to be executed by its duly authorized
representative as of the date first above written.

                                        SIRIUS LABORATORIES INC.

                                        By: /s/ Frank r. Pollard
                                            ------------------------------------
                                        Name: Frank R. Pollard
                                        Title: Vice Chairman

                                        ALTANA INC.

                                        By: /s/ Charles Moore
                                            ------------------------------------
                                        Name: Charles Moore
                                        Title: Vice President,
                                               Business Development

                                      -23-
<PAGE>

                                    EXHIBIT A

                               FINANCIAL APPENDIX

This Financial Appendix provides the definitions of certain financial terms
applicable to the Parties for purposes of this Agreement. It also covers
accounting policies and procedures to be followed in determining the Net Sales
for purposes of calculating the applicable royalty payments pursuant to this
Agreement. All capitalized terms used herein without definition shall have the
meanings ascribed thereto in the Agreement, unless otherwise expressly provided
herein.

For such purpose, this Financial Appendix sets forth the principles for
reporting actual results in the Territory, the frequency of reporting and the
methods of determining payments to the Parties, auditing of accounts and other
matters.

A.1  PRINCIPLES OF REPORTING

     The presentation of Net Sales and Commercialization Program shall be based
on the Company's financial information and shall be presented:

     1)   for each seller (the Company and each of its Affiliate) for the
          Product in the Territory

     2)   for all sellers on a consolidated basis for the Product in the
          reporting format depicted as follows:

<TABLE>
<S>            <C>
SALES
GROSS SALES:
Less
1.) [c.i.]
2.) [c.i.]
3.) [c.i.]
4.) [c.i.]
5.) [c.i.]
NET SALES
NO. OF UNITS
</TABLE>

     The presentation of the Development Program shall be based on Altana's or
Company's financial information for the Product:

                                       A-1

<PAGE>

<TABLE>
<S>                                <C>
DEVELOPMENT PROGRAM
Third Party Development Costs
Internal Development Costs
   Hours
   Charge-Out Rate
TOTAL INTERNAL DEVELOPMENT COSTS
TOTAL DEVELOPMENT COSTS
</TABLE>

     It is the intention of the Parties that the interpretation of these
definitions shall be consistent with GAAP. If necessary, a Party shall make the
appropriate adjustments to the financial information it supplies under the
Agreement to conform to the above format of reporting results of operation.

A.2  FREQUENCY OF REPORTING

     The [c.i.] shall be a [c.i.] commencing on [c.i.] during which the [c.i.].
A [c.i.] shall be a [c.i.] period commencing on the [c.i.] during which the
[c.i.] and subsequent consecutive [c.i.] periods.

     On a [c.i.] basis, the Company will provide Altana with a report, which
shall set forth each marketing quarter's Gross Sales and Net Sales of the
Product in Units, local currency and U.S. dollars (using the exchange rate as
set forth in Section 5.4 above) according to the Company's sales reporting
system, which shall be consistent with the definitions herein. Each report shall
be provided as early as possible, but in no event later than [c.i.] after the
last marketing quarter in question, and shall provide quarterly and marketing
year-to-date cumulative figures.

A.3  DEFINITIONS

     "Development Costs" means the development costs [c.i.] by Altana from
[c.i.] through the later of: (i) the date of [c.i.] (including thereafter costs
to [c.i.]) of the Product in the Territory; or (ii) the date of [c.i.] of the
Product for which [c.i.] in the Territory.

     Development Costs with respect to a Product shall each include [c.i.] and
[c.i.] incurred in the conduct of a Development Program, including but not
limited to the following:

     (i) [c.i.] and to [c.i.];

     (ii) [c.i.], including costs of [c.i.] conducted internally or by
individual investigators or consultants necessary for the purpose of maintaining
and/or expanding marketing approval of a Product;

     (iii) costs for [c.i.] for the purpose of submission to the FDA to obtain
marketing approval and/or expand marketing approval of a Product; and

     (iv) expenses for [c.i.] associated with the clinical testing program or
post-marketing studies required to maintain product approvals.

                                       A-2

<PAGE>

     In determining Development Costs chargeable under the Agreement, each Party
shall use its respective project accounting systems and shall review and approve
its respective project accounting systems and methodologies with the other
Party.

     "Distribution Costs" means the costs [c.i.].

     "First Commercial Sale" means, with respect to the Product, the first sale
for which payment has been invoiced for use or consumption by the general public
of such Product in the Field in the Territory after all required Registrations,
including pricing approvals (if applicable), have been granted by the FDA in the
Territory.

     "Fully Absorbed Manufacturing Cost" means, if manufactured by Altana or its
Affiliates, with respect to the Product, the fully-burdened cost of
manufacturing, assembling, filling and packaging of the Product expressed on a
per unit manufactured basis, including the cost of (i) [c.i.], and (ii) [c.i.]
or [c.i.] incurred or spent in the [c.i.] including without limitation for
[c.i.], and (iii) [c.i.] (including [c.i.], and (iv) [c.i.] or any part thereof
as incurred or spent by Altana or its Affiliates in connection with the supply
of the Product pursuant to the terms of a supply agreement, and (v) and [c.i.]
as invoiced to Altana, provided, that, any such [c.i.] shall be based on the
same cost components of the sub-contractor as described in (i) through (iv)
hereof plus a [c.i.] margin, all as determined in accordance with generally
accepted accounting principles consistently applied.

     "Internal Development Costs" with respect to Development Program
activities, shall mean the [c.i.] by Altana's employees on undertaking the
Development Program. Altana will undertake such work at [c.i.] reflecting
Altana's contribution to the development of the project and economies of scale.

     "Net Sales" means,

          (a) with respect to the Product, the gross amount invoiced for sales
of a Product in arm's length sales by the Company or its Affiliates to Third
Parties, commencing with the First Commercial Sale of such Product, less the
following deductions from such gross amounts which are [c.i.]:

               (i)  [c.i.];

               (ii) [c.i.];

               (iii) [c.i.];

               (iv) [c.i.]

               (v)  [c.i.]

          (b) shall also include [c.i.]. [c.i.] shall use [c.i.] to reconcile
such amounts invoiced and deducted annually for the Product. For the avoidance
of doubt, Net Sales shall not include [c.i.]. Net Sales, as set forth in this
definition, shall be calculated applying, in accordance with GAAP, the standard
accounting practices the Company customarily applies to other products sold by
it.

          (c) For a Combination Sales, the Parties shall meet approximately
[c.i.] prior to making a particular type of Combination Sale involving a Product
to negotiate in good faith and agree to an appropriate adjustment to Net Sales
to reflect the relative significance of the Product(s) and other
products/services included within such Combination Sales or royalty

                                       A-3

<PAGE>

bearing fraction of such Combination Sales. If, after good faith negotiations
(not to exceed [c.i.], which can be extended by mutual agreement), the Parties
cannot agree to an appropriate adjustment, Net Sales shall be equal to [c.i.] of
all of the products and services included within Combination Sales multiplied by
a fraction, the numerator of which is the [c.i.] of the component(s) of said
Combination Sales, which cause said component(s) to be a Product, if sold
separately and the denominator of which is the [c.i.] of the Combination Sales
as a whole.

     "Third Party Development Costs" with respect to Development Program
activities, shall mean all costs paid to third party sub-contractors by Altana
for work undertaken on Development Program activities.

     "Units" shall mean the number of units of such Product sold or transferred
during the period and included in Net Sales.

                                       A-4

<PAGE>

                                    EXHIBIT B

                        ALTANA'S DEVELOPMENT TESTING PLAN

[c.i.] - Sirius Labs Projected Costs

     The following is an updated estimate of the timeline and development costs
     for the above-referenced project. This estimate is based on the following
     assumptions:

     1.   Altana's [c.i.] can be used with only minor modifications for the
          [c.i.],

     2.   Altana's current analytical methods can be used to assay the product,

     3.   [c.i.] has a pre-established tox/safety profile, and

     4.   Proposed product will be marketed with [c.i.]. [c.i.] will be used.

PROJECT SCOPE: develop an [c.i.]

     The timeline and projected costs for this project have been prepared based
on discipline in the following table.

<TABLE>
<CAPTION>
A. DISCIPLINE   B. TIME                 SCOPE OF WORK                DIRECT COST
-------------   -------                 -------------                -----------
<S>             <C>       <C>                                        <C>
                [c.i.]    Formulation development & methods
                          development
                [c.i.]    Exhibit batch manufacture (1 batch)
       R&D                Materials & components,
                          testing & release
                          IP and FP testing & release
                [c.i.]    Stability testing (1 batch)

                [c.i.]    Franz Cell In-vitro Study (cadaver skin)       [c.i.]
    Clinical    [c.i.]    Dermal Irritation Study                        [c.i.]
                          Skin Sensitization Study

   Regulatory   [c.i.]    Prior-Approval Supplement
                          (final formulation to product launch)

C.   TOTALS     [C.I.]                                                   [c.i.]
</TABLE>

The overall project timeline is [c.i.] with an approximate cost of [c.i.] for
[c.i.]. [c.i.] to be billed as specified in Exhibit A3.

                                       B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]